PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index

Clinical use of doxorubicin (Dox) is limited by cumulative myelo- and cardiotoxicity. This research focuses on the detailed characterization of PhAc-ALGP-Dox, a targeted tetrapeptide prodrug with a unique dual-step activation mechanism, designed to circumvent Dox-related toxicities and is ready for...

Descripción completa

Detalles Bibliográficos
Autores principales: Casazza, Andrea, Van Helleputte, Lawrence, Van Renterghem, Britt, Pokreisz, Peter, De Geest, Natalie, De Petrini, Marzia, Janssens, Tom, Pellens, Marijke, Diricx, Marjan, Riera-Domingo, Carla, Wozniak, Agnieszka, Mazzone, Massimiliano, Schöffski, Patrick, Defert, Olivier, Reyns, Geert, Kindt, Nele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377749/
https://www.ncbi.nlm.nih.gov/pubmed/35149549
http://dx.doi.org/10.1158/1535-7163.MCT-21-0518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377749/
https://www.ncbi.nlm.nih.gov/pubmed/35149549
http://dx.doi.org/10.1158/1535-7163.MCT-21-0518

Ejemplares similares